Paxlovid Boceprevir Intermediate CAS 565456-77-1 Assay ≥99.0%
Nbunye azụmaahịa PF-07321332 Ndị mmekọ Paxlovid nwere ogo dị elu.
L-tert-Leucine (H-Tle-OH) CAS 20859-02-3
Caronic Anhydride CAS 67911-21-1
(1R,2S,5S)-6,6-Dimethyl-3-azabicyclo[3.1.0]hexane-2-Carboxylic Acid Methyl Ester Hydrochloride 565456-77-1
Methyl (S)-2-(Boc-amino) -3-[(S) -2-oxo-3-pyrrolidinyl] propanoate CAS 328086-60-8
6,6-Dimethyl-3-azabicyclo[3.1.0] hexane CAS 943516-54-9
Aha Chemical | (1R,2S,5S)-6,6-Dimethyl-3-azabicyclo[3.1.0]hexane-2-Carboxylic Acid Methyl Ester Hydrochloride |
Ụdị okwu | Methyl (1R,2S,5S) -6,6-dimethyl-3-azabicyclo[3.1.0] hexane-2-carboxylate Hydrochloride |
Nọmba CAS | 565456-77-1 |
Nọmba CAT | RF-PI318 |
Ọnọdụ Ahịa | N'ọkwa, Mpụta Ihe ruru Tọn |
Usoro ihe omimi | C9H15NO2.ClH |
Ibu molekụla | 205.683 |
Ụdị | Ruifu Chemical |
Ihe | Nkọwapụta |
Ọdịdị | Ọcha ka Gbanyụọ-Ọcha ntụ ntụ |
njirimara A | IR: Yiri ihe ntụaka |
njirimara B | Oge njide: Yiri ihe ntụaka |
Entiomer | ≤0.15% |
adịghị ọcha emetụtara (nke HPLC) | |
Adịghị ọcha amaghi ama | ≤0.20% |
Mgbakọta adịghị ọcha | ≤1.0% |
Mmiri | ≤0.50% |
Ihe fọdụrụ na mgbanye | ≤0.10% |
Ọla dị arọ | ≤20ppm |
Nyocha | ≥99.0% |
Nlele ọkọlọtọ | Standardkpụrụ ụlọ ọrụ |
Ojiji | Ọkara nke PF-07321332 Paxlovid (CAS 2628280-40-8) na Boceprevir (CAS 394730-60-0) |
ngwugwu: Kalama, Aluminom foil bag, kaadiboodu drum, 25kg / Drum, ma ọ bụ dị ka ndị ahịa chọrọ.
Ọnọdụ Nchekwa:Na-echekwa n'ime akpa ndị a kpuchiri ekpuchi na ebe dị jụụ na nke kpọrọ nkụ;Chebe site na ọkụ, mmiri mmiri na ụmụ ahụhụ.
(1R,2S,5S)-6,6-Dimethyl-3-azabicyclo[3.1.0]hexane-2-Carboxylic Acid Methyl Ester Hydrochloride (CAS 565456-77-1) bụ azabicyclohexane ewepụtara eji na nkwadebe nke ịba ọcha n'anya C. nje virus (HCV) NS3 serine protease inhibitor.Ọ bụ etiti nke PF-07321332 Paxlovid (CAS 2628280-40-8) na Boceprevir (CAS 394730-60-0).PF-07321332 bụ onye na-egbochi SARS-CoV 3C dị ka protease (3CLPRO) na-arụ ọrụ.PF-07321332 lekwasịrị anya na nje SARS-CoV-2 ma enwere ike iji ya mee nyocha COVID-19.Boceprevir (INN, ahia aha Victrelis) bụ protease inhibitor eji dị ka ọgwụgwọ maka ịba ọcha n'anya C genotype 1. Ọ na-ejikọta HCV nonstructural 3 NS3 (HCV) saịtị nọ n'ọrụ.Ọ bụ Schering-Plough na-emepụta ya, mana Merck na-emepụta ya ugbu a ebe ọ bụ na e nwetara Schering na 2009. FDA kwadoro ya na May 13, 2011.